SENOVAC
神诺威
Pioneering Immuno-senolytic Therapies. Developing vaccines and antibody drugs for age-related diseases like fibrosis and metabolic syndrome.
免疫抗衰疗法的先行者。针对老龄相关疾病（如纤维化和代谢综合征）开发突破性的疫苗及抗体药物。
Our Science 探索我们的科学
Targeting the root cause of aging to extend healthy lifespan.
直击衰老根源，延长人类健康寿命。
Aging is the biggest risk factor for chronic diseases. Current solutions lack tissue specificity or have high toxicity. China alone will have 400 million people over 60 by 2035.
衰老是慢性疾病最大的风险因子。现有的抗衰手段往往缺乏组织特异性或存在毒性风险。面对老龄化社会的万亿级需求，我们需要更安全有效的方案。
We benchmark tumor immunotherapy principles to clear senescent cells. Our goal: Rejuvenate, Prevent Chronic Diseases, Extend Healthspan, & Delay Ageing.
我们对标肿瘤免疫疗法，利用免疫系统精准清除衰老细胞。目标：防治老年慢性病、延长健康寿命、延缓衰老、重焕青春活力。
Built on SenoVac's expertise in aging biology and immune clearance, our AI platform turns scientific insight into therapeutic opportunity, uncovering tissue-selective seno-antigens and expanding treatment possibilities for age-related diseases.
依托神诺威在衰老生物学与免疫清除领域的长期积累，AI平台将科研洞见转化为可推进的药物机会，持续发现具有组织选择性的Seno-antigen，拓展衰老相关疾病的治疗边界。
We focus on the defining differences between pathological senescent cells and healthy tissue to build an actionable seno-antigen landscape.
聚焦病理性衰老细胞与健康组织之间最关键的差异，建立Seno-antigen靶点版图。
We align each target's biology with an immune-clearance strategy, moving promising discoveries toward validation and therapeutic translation.
围绕每个靶点的生物学特征匹配免疫清除策略，使创新发现更快进入可验证、可转化的药物研发阶段。
SenoVac combines selective Seno-antigen discovery with immune-engineered therapeutic routes to clear pathological senescent cells, reduce SASP-driven inflammation and support tissue repair.
神诺威将选择性Seno-antigen发现与免疫工程治疗路径相结合，清除病理性衰老细胞，降低SASP驱动的炎症负担，并促进组织修复。
Surface antigens distinguish pathological senescent cells from healthy tissue. We translate these targets into complementary vaccine, engineered immune-cell, antibody/TCE and ADC strategies.
通过表面抗原区分病理性衰老细胞与健康组织，并将靶点转化为疫苗、工程化免疫细胞、抗体/TCE及ADC等互补治疗策略。
More than 25 years of aging-biology research across animal and cell models, reporting systems and translational practice guides target selection and validation.
超过25年的衰老生物学研究积累，覆盖动物与细胞模型、报告系统及转化实践，持续指导靶点选择与验证。
Harness immune recognition to selectively eliminate senescent cells and reduce SASP-driven inflammation, enabling tissue repair and functional recovery.
利用免疫识别选择性清除衰老细胞，降低SASP炎症因子负担，从而促进组织修复与功能恢复。
We integrate multi-omics, single-cell profiling and functional validation to identify tissue-selective seno-antigens suitable for drug development.
整合多组学、单细胞与功能验证，系统发现具组织选择性的衰老抗原，为药物开发提供可转化靶点。
Deep learning accelerates target mining and triage; generative AI supports rapid optimization of bispecific/TCE and ADC designs.
深度学习加速靶点挖掘与优先级排序；生成式AI支持双抗/TCE与ADC的快速优化迭代。
Advanced by our AI-enabled Seno-antigen discovery platform.
由AI驱动的Seno-antigen发现平台持续推进。
| Program 项目名称 | Indication 适应症 | Modality 药物形式 | Development Stage 研发阶段 |
|---|---|---|---|
| HDT011 | Obesity & Metabolic Syndrome 肥胖与代谢综合征 | Peptide drug / Antibody 多肽药物 / 抗体 | Pre-clinical / IIT Prep 临床前 / IIT准备 |
| HDT012 | Pulmonary Fibrosis (IPF) 特发性肺纤维化 (IPF) | Bispecific Antibody 双特异性抗体 | Lead Optimization 先导化合物优化 |
| Pet-Seno | Pet Anti-aging 宠物抗衰老 | Vaccine 疫苗 | IND Enabling IND 申报准备 |
| Sen-ADC | Aging-related diseases / Organ premature aging 衰老相关疾病 / 器官早衰 | ADC 抗体偶联药物 | Discovery 发现阶段 |
Founder Scientist
创始科学家
HKU Professor, 30+ years in aging research.
香港大学教授，30+年衰老研究经验。
Chief Medical Officer
首席医学官
Former Associate Professor, University of Chicago.
前芝加哥大学副教授。
CEO / CFO
首席执行 / 财务官
30 years in capital markets; 15+ years in healthcare investment.
近30年资本市场经验，15+年医疗投资经验。
CTO
首席技术官
HKU PhD; 10+ years in anti-aging R&D.
港大博士，10+年抗衰研发经验。
Flat 1309,13/F King's Commercial Building，NO.2-4 Chatham Court,
100 T.S.T Kln，Hong Kong
香港九龍尖沙咀漆咸圍2-4號
金時商業大廈13樓1309室
Backed by HKU DeepTech100 & ITC TSSSU-O
香港大学 DeepTech100 项目支持
香港创新科技署 TSSSU-O 资助
Source: Company Pitch Deck. (Contact us for details.)
资料来源：公司路演材料（详细信息请联络我们）。